Clinical Trial Detail

NCT ID NCT03412565
Title A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

multiple myeloma

Therapies

Bortezomib + Daratumumab + Dexamethasone + Melphalan + Prednisone

Daratumumab + Dexamethasone + Lenalidomide

Bortezomib + Daratumumab + Dexamethasone + Lenalidomide

Age Groups: senior adult

No variant requirements are available.